451 results about "Regenerative medicine" patented technology

The invention provides an anticoagulant coating for medical instruments, which can be used in the field of regenerative medical instruments. The prepared anticoagulant coating has short-term and long-term anticoagulant performance, and in addition, the thrombin responsive nanoparticles wrapped in the hydrogel coating can selectively release a factor Xa (FXa) inhibitor apixaban according to needs, so that thrombosis is inhibited in the middle stage of implantation. In-vitro and in-vivo experimental evidences show that after the material is implanted for a long time, an organized endodermis can be seen on the surface of the material, and the material has a special antithrombotic characteristic. The dynamic adjusting system has a multi-layer protection mechanism, and a new thought can be provided for designing the surface of a contact blood material adapting to environmental conditions.

Provided herein are devices and methods that represent a dual function approach to tissue engineering and regenerative medicine, particularly for bone fracture or segmental defect healing. The devices include an implantable substrate; a first active composition, and a second active composition that comprises one or more oxygen-modulating compositions. The incorporation of dual bioactive compositions on the substrate offers a versatile platform for manipulating cells and modulating the local tissue oxygen environment at the site of implantation.

The present invention discloses a method for enhancing cardiomyocyte production from induced pluripotent stem cells (iPSCs) by adjusting the culture medium exchange process during the transition from WNT activation to inhibition for differentiation. Instead of completely replacing the culture medium, this innovative technique involves partially changing the medium, which allows for a controlled exposure to WNT activators concurrent with the introduction of WNT inhibitors. This key modification in the protocol markedly increases the consistency and efficiency of cardiomyocyte generation, reducing variability between batches. By fine-tuning the medium exchange process, this method streamlines the creation of cardiomyocytes for use in regenerative medicine, emphasizing the critical adjustment phase within the culture conditions.

The invention belongs to the technical field of biomedical materials and regenerative medicine, and relates to collagen-based injectable fiber hydrogel as well as a preparation method and application thereof. According to the injectable fiber hydrogel, methacrylated collagen and dithiothreitol are subjected to a thiol-ene click reaction rapidly under the action of a photoinitiator through illumination, a primary cross-linked network is formed, and the injection and in-situ gel forming requirements are met; then under the conditions that the pH is 6.5-8.0 and the temperature is 30-39 DEG C, collagen molecules are self-assembled into a nanofiber structure, and a bionic network similar to a natural extracellular matrix is obtained. The hydrogel disclosed by the invention has the advantages of rapid gelation, structural biomimetic property and biological activity; residual sulfydryl endows the hydrogel with active oxygen scavenging capacity, so that oxidative stress can be relieved, and immune response can be regulated; the fibrotic structure promotes cell adhesion, migration and tissue regeneration.

The invention discloses stem cell freeze-dried powder for promoting skin healing and a preparation method of the stem cell freeze-dried powder. The freeze-dried powder comprises an effective component, a freeze-drying protective agent group and a polymer protective agent group, the effective component is umbilical cord mesenchymal stem cell conditioned medium freeze-dried supernatant, the protective agent group is selected from one or more of cane sugar, trehalose, lactose and mannitol, and the polymer protective agent group is selected from one or more of polyvinylpyrrolidone (PVP) and glucan. The preparation method comprises the following steps: collection of a conditioned culture medium, preparation of a freeze-drying protective agent solution, mixing treatment, low-temperature pre-freezing and freeze-drying, collection and packaging of freeze-dried powder and the like. The method can effectively retain stem cell-derived active factors and enhance the stability and redissolvability of the freeze-dried powder, and is suitable for skin wound repair, regenerative medicine and other scenes.

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention discloses a culture method of high-activity human urine-derived stem cells, which relates to the technical field of biological medicine, and is technically characterized by comprising the following steps: collecting urine samples of pregnant and lying-in women, coating a culture plate with gelatin, inducing adherence, performing passage amplification, performing immunofluorescence identification, performing function detection and other optimized conditions, and separating and culturing the stem cells. Compared with urine-derived stem cells of normal adults, the stem cells derived from pregnant women have stronger activity, higher dryness and faster multiplication capacity. The invention provides a novel and superior cell source for tissue engineering and regenerative medicine.

The invention discloses a multifunctional hydrogel patch and a preparation method and application thereof.The biological patch comprises decellularized freeze-dried tumor tissue (dFCT) and a hydrogel layer loaded with hair melanin nanoparticles (HNPs), the dFCT is obtained by decellularizing and freeze-drying the tumor tissue, and rich natural extracellular matrix components are reserved; hNPs is extracted from hair and has excellent active oxygen scavenging capacity and photothermal conversion performance; it is preferable that the hydrogel layer is a methacrylated gelatin (GelMA). The patch disclosed by the invention shows a remarkable cell viability promoting effect and antibacterial ability in vitro, and can accelerate wound healing by reducing oxidative stress, inhibiting inflammatory response and promoting angiogenesis in vivo. The patch is simple and convenient in preparation process and natural in component source, has multiple functions of resisting bacteria, resisting oxidation, promoting tissue regeneration and the like, and is suitable for wound repair treatment.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

The invention belongs to the technical field of biological analysis and evaluation, and particularly relates to a stem cell differentiation process multi-modal image fusion and intelligent evaluation method, which comprises a stem cell differentiation process multi-modal image fusion method: on the basis of constructing a multi-modal near-physiological mechanics microenvironment, carrying out image analysis by adopting the multi-modal image fusion method; an intelligent evaluation method for the stem cell differentiation process: developing an intelligent evaluation method based on deep learning driving on the basis of constructing a multi-modal near-physiological mechanical microenvironment, and revealing a mechanical-epigenetic regulation mechanism; the synergistic application of the two solves the core observation and regulation problems in stem cell differentiation research, and provides an industrialized intelligent platform for regenerative medicine. According to the method, the data integrity can be improved, the resolution limitation is broken through, the experiment process is accelerated, accurate mechanism analysis can be realized, automatic decision making is promoted, and the research and development cost is reduced.

The invention provides a culture medium composition and a method for preparing mesenchymal stem cells. The culture medium combination comprises a culture medium A, a culture medium B and a differential culture medium, the culture medium A comprises a basic culture medium and a first small molecule compound combination, the culture medium B comprises a basic culture medium and a second small molecule compound combination, and the differential culture medium comprises a basic culture medium and a third small molecule compound combination. According to the culture medium and the method, the MSC can be prepared through ES or iPSC, and the culture medium and the method can be widely applied to the fields of regenerative medicine, tissue engineering, immunotherapy and the like.

The invention relates to a nerve repair guide catheter, a preparation method and application, an electrostatic spinning technology is adopted to construct a nanofiber membrane which is directionally and orderly arranged so as to guide nerve axons to directionally grow, and cell energy metabolism is promoted and tissue repair and regeneration are accelerated through metabolism and conversion of degradation products. Therefore, the nerve injury repairing effect better than that of traditional matrix materials without biological activity, such as PCL, is achieved. According to the invention, a novel solution is provided for solving the problem of insufficient biological activity of a traditional nerve conduit material by constructing a degradable high polymer material with biological activity. Therefore, the regeneration efficiency of peripheral nerve injury repair is improved, and the application prospect of the bioactive material in the fields of tissue engineering and regenerative medicine is expanded.

The present disclosure provides a hydrogel composition for tissue engineering and regenerative medicine, including naturally derived polymers functionalized with furan groups and nanoparticles of poly(lactic-co-glycolic acid)-poly(ethylene glycol) copolymer functionalized with maleimide groups. Covalent crosslinking via a bioorthogonal Diels-Alder click reaction forms a tunable, biocompatible, and biodegradable three-dimensional network. The hydrogel composition mimics the extracellular matrix and offers adjustable mechanical properties, controlled biodegradation, and therapeutic agent delivery for applications such as cartilage regeneration and drug delivery.

The invention provides a treatment system for promoting dental pulp repair by using oral stem cells, and relates to the technical field of oral treatments.According to the treatment system, through the synergistic effect of a dynamic gene regulation and control module, a self-adaptive intelligent support and a biological digital fusion interface, the dental pulp repair is promoted through the dynamic gene regulation and control module and the self-adaptive intelligent support; the dynamic gene regulation and control module adopts a light-operated CRISPR system, carries out real-time gene editing on dental pulp stem cells and carries out dynamic adjustment according to regeneration stage requirements, and the self-adaptive intelligent stent is based on a 3D printing technology, is manufactured in combination with a patient tooth digital model and can dynamically release growth factors and optimize a microenvironment; through combination of personalized design and dynamic regulation and control, adaptive adjustment can be performed according to specific requirements of patients, so that not only is the repair efficiency of dental pulp tissues improved, but also the success rate of functional reconstruction is increased, more efficient and accurate treatment selection is provided for the patients suffering from dental pulp injury, and personalized development of oral regenerative medicine is promoted.

The invention is suitable for the technical field of bioengineering, and provides an endometrial organ model based on a micro-fluidic chip technology and a construction method thereof. According to the invention, an endometrial organ dynamic culture system based on a micro-fluidic chip technology is constructed, and the system can accurately simulate the in-vivo physiological microenvironment of endometrium, including key factors such as periodic mechanical stress, fluid shear force and intercellular interaction. Meanwhile, by comparing traditional 3D static culture with a micro-fluidic chip dynamic culture system, the remarkable advantages of dynamic culture in the aspects of organoid morphology, function and the like are defined, and the unique value of a micro-fluidic technology in construction of a highly-bionic endometrial organoid model is deeply reflected. An endometrial organ model constructed by the dynamic culture system can provide a reliable in-vitro platform closer to an in-vivo real state for pathogenesis research, drug screening, regenerative medicine research and the like of endometrial related diseases, and basic research and transformation application in related fields are assisted.

The invention relates to an extraction and culture method of urine-derived stem cells, and belongs to the field of cell biology and regenerative medicine. The method comprises the following steps: coating a culture plate with a gelatin solution; collecting clean midstream urine of healthy people and adding antibiotics; centrifugally separating the cell precipitate; washing with a phosphate buffer solution; re-suspending the precipitate by using a urine stem cell complete culture medium for primary culture; and after the cells grow to a certain fusion degree, carrying out passage amplification. The urine stem cell complete medium comprises a basic medium, fetal calf serum, epidermal growth factors, platelet-derived growth factors and basic fibroblast growth factors. By adopting the method disclosed by the invention, the urine-derived stem cells can be efficiently and stably separated from urine, and the obtained cells have high multiplication capacity, good stemness maintaining capacity, multidirectional differentiation potential and immunoregulation function, and can provide an ideal seed cell source for treating diseases such as diabetic erectile dysfunction.

The invention relates to the field of gel matrices and scaffold development; in particular for use in the field of tissue engineering and regenerative medicine (TERM) and provides for a water insoluble, thermo- stable, crosslinked gelatin matrix. The fabricated matrices of the invention can be applied directly into or onto the defect and the regenerative processes are allowed to take place according to the natural healing steps.

Provided herein are methods for manufacturing and using engineered tissues. The methods and compositions described herein may be useful for biocomputing, regenerative medicine, non-clinical trials, or cellular agriculture.

Osteoinductive materials and modular bioactive synthetic bone craft (MST) devices are provided. The MST devices comprise the osteoinductive materials for applications in regenerative medicine and treatment of diseases. The osteoinductive material can be characterized by a scaffold filament, a hydrogel layer cross-linked with the scaffold filament, and an osteoinductive growth factor. The hydrogel layer contains the osteoinductive growth factor, a covalent cross-linking polymer, a covalent cross-linking monomer, and a physical cross-linking polymer.

The invention relates to the technical field of bone tissue engineering and regenerative medicine, and discloses a stem cell-loaded bionic bone scaffold material, which comprises a bone scaffold main body, the bone scaffold main body is formed by compounding hydroxyapatite and a biodegradable high-molecular polymer and has a porous structure, the porosity is 70%-90%, the aperture range is 100-500 microns, and pores are communicated with one another; a vascularization induction factor slow release system is arranged in the porous structure of the bone scaffold main body, the stem cell-loaded bionic bone scaffold material does not need to take the autologous bone of a patient, and the problems of donor injury and limited sources are avoided; the composite scaffold is matched with low-immunogenicity stem cells, so that the risks of immunological rejection and disease transmission are avoided; the material has the advantages of good biocompatibility, mechanical matching with human bones, degradability, no secondary operation, promotion of vascular regeneration and stem cell osteogenesis, and realization of bone regeneration integration.

The invention discloses a culture method for hypoxia culture of umbilical cord mesenchymal stem cells, which comprises the following steps: hypoxia pre-adaptive culture: inoculating umbilical cord mesenchymal stem cells in a culture medium containing bFGF (basic fibroblast growth factor), glutathione, astragalus polysaccharide and salidroside, and transferring the umbilical cord mesenchymal stem cells into a 5% O2 environment after the umbilical cord mesenchymal stem cells are preliminarily adhered to the wall in a normal oxygen environment; performing low-oxygen enrichment culture: replacing a second culture medium containing astragalus polysaccharide, salidroside, D-ribose, sodium pyruvate and D-glucose, and promoting efficient cell proliferation under 2% O2; performing function strengthening culture: adding tanshinone IIA and GSK-269962A, inducing cells to secrete VEGF under 1% O2, and maintaining high dryness. According to the method, through the synergistic effect of the three-stage gradient oxygen concentration and the specific serum-free culture medium, the cell proliferation multiple is remarkably increased, the total apoptosis rate is reduced, VEGF secretion is promoted, the multidirectional differentiation potential is reserved, the culture method is standardized in operation, the serum-free culture medium is definite in component, and a high-quality stem cell culture scheme is provided for the field of regenerative medicine.

The invention discloses an implantable acellular matrix material and a preparation method thereof, and belongs to the field of biomedical materials. According to the method, natural animal tissues (such as pericardium, achilles tendon or small intestine submucosa) are used as raw materials, a low-temperature chemical combined decellularization treatment technology is adopted, and the method comprises the multi-step synergistic process of pre-cooling soaking balancing, low-temperature enzymolysis, low-concentration surfactant gradient permeation cleaning, low-temperature nuclease degradation, non-crosslinking sterilization and the like. Under the condition that the treatment temperature is strictly kept at 0-8 DEG C, cell components and genetic materials (the residual DNA content is 1t, and the dry weight is 8 ng / mg) are efficiently removed, and meanwhile the natural three-dimensional fine structure of an extracellular matrix (ECM), the integrity of collagen fibrils and key bioactive components (such as glycosaminoglycans (GAGs)) are reserved to the maximum extent. The host immunological rejection reaction of the obtained material is remarkably reduced, host cell ingrowth, vascularization and tissue function reconstruction can be effectively promoted after implantation, and the material is suitable for high-end implantation scenes such as soft tissue repair and regenerative medical stents.

The present disclosure describes systems and methods for cell therapy. Cells (e.g., stem cells, immune cells, cardiomyocytes, etc.) may be engineered to exhibit extended half-lives as compared to control cells (e.g., non-engineered cells). The cells may be engineered to exhibit increased proliferative activity as compared to control cells. In some embodiments, immune cells may be engineered to efficiently and specifically target diseased cells (e.g., cancer cells) while control cells are insufficient or unable to target the diseased cells. In some embodiments, stem cells or differentiated cells, such as myocardial cells, may be administered to a target tissue for enhanced tissue engineering or regenerative medicine. The engineered cells disclosed herein can be engineered ex vivo, in vitro, and in some embodiments in vivo. Engineered cells prepared ex vivo or in vitro may be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumor). The engineered cell may be autologous to the subject. Alternatively, the engineered cell may also be allogeneic to the subject.

The invention discloses an umbilical cord mesenchymal stem cell serum-free culture medium, which is composed of a basic culture medium and additive components, and the additive components comprise, by final concentration, 5-20 [mu] g / mL of astragalus polysaccharide, 0.5-2.0 [mu] g / mL of salidroside, 0.1-0.5 [mu] g / mL of tanshinone IIA, 0.1-0.3 mg / mL of sodium pyruvate, 5-15 mM of D-ribose, 3-6 mg / mL of recombinant human albumin, and 5-10 [mu] g / mL of recombinant transferrin; the invention also discloses a method for culturing umbilical cord mesenchymal stem cells under the hypoxia condition by using the serum-free culture medium. The method comprises the steps of cell inoculation, culture under the hypoxia condition, subculture, cell passage and the like. The astragalus polysaccharide, the salidroside, the tanshinone IIA, the sodium pyruvate, the recombinant human albumin and the recombinant transferrin are added into the serum-free culture medium, so that nutrition supply and function maintenance of cells under a low-oxygen condition are guaranteed, the proliferation rate and the differentiation capacity of the cultured cells are improved, the apoptosis rate of the cells is reduced, and the survival rate of the cells is increased. Wide application prospects are realized in the fields of cell culture, regenerative medicine and the like.

The invention relates to a cellulose-based hydrogel prepared based on a cellulose copolymer, a cellulose derivative copolymer or a blend thereof, ultramicro fibers of cellulose form a net structure, and the cellulose-based hydrogel has a highly-ordered three-dimensional micro-nano structure, is better in transparency and is more beneficial to observation of a cell state. The cellulose-based hydrogel is suitable for culture of 3D cell culture tissues and organoids, the stem cells cultured by the cellulose-based hydrogel can form cluster culture stem cells and organoids, the operation is simple, compact fused monolayer endoderm cells are formed, non-directional differentiation of the stem cells can be inhibited, and the formed organoids are thick in vesicle wall and are in a solid shape. And the obtained product is a differentiated mature organ and can be used for high-throughput drug screening, drug toxicity testing and regenerative medicine.

The invention belongs to the technical field of regenerative medicine, and particularly relates to a method for generating vascular endothelial cells by inducing pluripotent stem cells to differentiate in vitro. The method comprises the following steps: carrying out first culture on pluripotent stem cells in a differential medium I to obtain cells A; carrying out second culture on the cell A in a differential culture medium II, and differentiating and directionally forming an endoderm cell B; performing third culture on the endoderm cells B in a differential culture medium III to obtain differentiated cells C; carrying out fourth culture on the differentiated cells C in a differentiation culture medium IV, and differentiating to form differentiated cells D; carrying out fifth culture on the differentiated cells D in a differential culture medium V, and differentiating to obtain vascular endothelial cells; wherein the differential culture media I-V do not contain activin A, VEGF (vascular endothelial growth factor) and BMP4 (bone morphogenetic protein 4). The method can improve the differentiation efficiency of the IPS cells to the vascular endothelial cells, and has a wide prospect in the cell therapy industry.

The main objective of this invention is to provide a novel manufacturing method capable of efficiently and directly converting or inducing somatic cells into insulin-producing cells. As an example, a method for manufacturing insulin-producing cells is provided, which involves directly differentiating and inducing insulin production from somatic cells. This method includes a step of culturing somatic cells in a serum-free differentiation-induction medium; or a step of culturing somatic cells in a differentiation-induction medium containing 5 μg / mL or more of insulin. According to this invention, insulin-producing cells with high insulin secretion capacity can be efficiently and directly manufactured from somatic cells. The insulin-producing cells obtained by this invention are useful in regenerative medicine and the like.

The present disclosure relates generally to methods and systems of producing Schwann cells from pluripotent stem cells under fully defined conditions. The Schwann cells produced by the disclosed methods find applications as models of the enteric nervous system, tools for high throughput screening of potential therapeutics for treatment of enteric neuropathies, and in regenerative medicine.

The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

The invention discloses a preparation method of a mouse skin organoid, which comprises the following steps: separating dermis and epidermis of an E18.5 mouse to obtain dermis cells, mixing the dermis cells with back skin cells of an E14.5 embryo mouse, mixing by using Matrigel to form cell spheres, and gradually forming the skin organoid in in-vitro culture; the organoid is mainly applied to batch production of organoid containing hair follicles. The invention relates to the technical field of stem cells and regenerative medicine. According to the preparation method of the mouse skin organoid, a cell source is improved in the experiment process, the mouse skin organoid containing hair follicles can still be formed after cells in the early development stage are added, and related developmental biology research is carried out. And the source of another dermal cell is not limited to late pregnancy, and also can be a newborn mouse, so that the source of seed cells is expanded, and the cost is reduced.